A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

Holkova, Beata, Zingone, Adriana, Kmieciak, Maciej · Clinical Cancer Research · 2016